Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy

Register of interests - TA655 (PDF 116 KB)

Equality Impact Assessment (Guidance development) - TA655 (PDF 146 KB)

Final draft guidance: TA655

Final appraisal document - TA655 (PDF 229 KB)

Committee papers - TA655 (PDF 1.94 MB)

Public committee slides - TA655 (PDF 886 KB)

Final scope - TA655 (PDF 166 KB)

Final stakeholder list - TA655 (PDF 238 KB)

Final appraisal document - TA483 (PDF 520 KB)

Committee papers - TA483 (PDF 4.49 MB)

Public committee slides - TA483 (PDF 429 KB)

Committee papers Managed Access Agreement - TA483 (PDF 674 KB)

Appraisal consultation document (PDF version) - TA483 (PDF 350 KB)

Committee papers - TA483 (PDF 2.46 MB)

Public committee slides August 2016 - TA483 (PDF 513 KB)

Public committee slides February 2016 - TA483 (PDF 467 KB)

Appraisal consultation document (PDF version) - TA483 (PDF 456 KB)

Committee papers - TA483 (PDF 8.66 MB)

Final scope - TA483 (PDF 107 KB)

Final stakeholder list - TA483 (PDF 176 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA483 (PDF 309 KB)

Equality impact assessment (Scoping) - TA483 (PDF 119 KB)